Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway

Figure 2

Exe attenuates oxidative stress and liver injury after four weeks of treatment: (a) serum MDA levels; (b) liver MDA levels; (c) serum ALT levels; (d) liver ALT levels. Data are expressed as (n = 7-8). , , and , model versus control group; , , , and , Exe versus model group. Exe: exenatide; MDA: malondialdehyde; ALT: alanine aminotransferase.

(a)

(b)

(c)

(d)